Enveda Biosciences Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2019

Location

Boulder CO US

Primary Industry

Biotechnology

About

Based in California, US, and founded in 2019 by CEO Viswa Colluru, Enveda Therapeutics, Inc., d/b/a Enveda Biosciences is a biotechnology company that uses a uses a drug platform to construct and decode integrated datasets of anthropological, biological, and chemical information from medicinal plants to inspire new medicines. In November 2024, Enveda Biosciences raised USD 130 million in series C funding co-led by returning investors Kinnevik and FPV Ventures, with participation from new investors Baillie Gifford and Cresset Partners. Other returning investors PremjiInvest, Lingotto Investment Management, Lux Capital, Dimension Ventures, True Ventures, Nature Conservancy Endowment, an individual, and other unspecified investors also participated in the round. Enveda Biosciences uses advanced technology to leverage natural products for drug discovery. The company’s platform identifies and harnesses the diverse chemical properties and biological activities found in nature, which traditional small molecule libraries cannot match. Enveda's approach includes discovering new medicines by exploring novel chemistries to manipulate disease-relevant proteins and uncovering new drug targets through the study of natural compounds. The firm’s pipeline focuses on therapies for inflammation, fibrosis, pain, and dermatological conditions, utilizing both oral and topical formulations. Enveda's technology platform overcomes challenges in bioactivity annotation and structure elucidation, providing a prolific source of next-generation compounds. The company plans to use its proceeds from November 2024 funding to advance clinical programs with commercial potential in 2025 and 2026, support the development of 10 pipeline candidates and multiple discovery programs, and invest in its platform.

Current Investors

True Ventures, Wireframe Ventures, Village Global

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Pharmaceutical Research & Development

Website

www.envedabio.com

Verticals

Artificial Intelligence

Company Stage

Series C

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.